menu search

Rxsight, inc. to present at the j.p. morgan healthcare conference

ALISO VIEJO, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) — (NASDAQ: RXST) RxSight, Inc., an ophthalmic med...

December 28, 2022, 9:05 pm

Outlook therapeutics announces $25 million registered direct offering priced at-the-market under nasdaq rules

ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch ...

December 23, 2022, 11:00 am

Outlook therapeutics announces validation of marketing authorization application by ema for ons-5010 as treatment for wet amd

Outlook Therapeutics Inc (NASDAQ:OTLK) announced the validation of the company's Marketing Authorization Application (MAA) by the European Medicines A...

December 22, 2022, 9:01 am

Skye bioscience receives us fda authorization of investigational new drug application for sbi-100 oe

Skye Bioscience Inc (OTCQB:SKYE) said the US Food and Drug Administration (FDA) has authorized it to proceed with the Investigational New Drug (IND) ...

December 20, 2022, 7:53 am

Skye bioscience says dosing completed of sbi-100 ophthalmic emulsion in the first cohort of the single ascending dose part of its phase 1 study

Skye Bioscience Inc (OTCQB:SKYE) said it has completed dosing of SBI-100 ophthalmic Emulsion (OE) in th...

December 16, 2022, 7:34 am

Okyo pharma ipo: innovative treatment for xerophthalmia

The IPO of OKYO Pharma Limited will take place on 15 December on the NASDAQ exchange. The company is engaged in the development of drugs for the treat...

December 15, 2022, 2:21 pm

Harrow health forges agreement to acquire exclusive us rights to blockbuster novartis eyecare drugs

Harrow Health Inc (NASDAQ:HROW) revealed that it has forged a binding agreement for the acquisition of the exclusive US commercial rights to five Food...

December 14, 2022, 12:07 pm

Titan pharmaceuticals inc. announces licensing agreement with ocular therapeutix inc.

SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that i...

December 12, 2022, 11:30 am

Alcon's (alc) latest buyout to enhance its product portfolio

Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding...

November 24, 2022, 3:48 pm

Skye bioscience recruits patients for first cohort in trial to treat glaucoma with ophthalmic drug

Skye Bioscience Inc (OTCQB:SKYE) said it has started screening for its first-in-human Phase 1 trial of SBI-100 ...

November 16, 2022, 9:22 am

Outlook therapeutics® to present at the h.c. wainwright 24th annual global investment conference

ISELIN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to deve...

September 7, 2022, 8:05 am

Outlook therapeutics re-submits biologics license application for ons-5010 as a treatment for wet amd to the fda

Outlook Therapeutics Inc (NASDAQ:OTLK) said it has re-submitted its biologics license application (BLA) to the US Food and Drug Administration (FDA) f...

August 30, 2022, 9:49 am

Alcon to acquire aerie pharmaceuticals for $15.25 a share

Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share....

August 23, 2022, 3:45 am

Outlook therapeutics ends 3q with $26 million in cash and cash equivalents; plans to re-submit ons-5010 application by september

Outlook Therapeutics (NASDAQ:OTLK) Inc said it ended the fiscal third quarter with $26 million in cash and cash equivalents that are expected to fun...

August 10, 2022, 10:01 am

Valeo pharma enters commercialization and supply agreement with novartis canada for two ophthalmic therapies

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it has entered into a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc fo...

August 2, 2022, 8:01 am

Aldeyra's (aldx) dry eye disease chamber study meets goals

Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for...

July 13, 2022, 1:05 pm

Aldeyra's reproxalap hits primary goals in dry eye disease chamber crossover trial

Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoints in a crossover clinical trial of 0.25% reproxalap ...

July 12, 2022, 9:03 am

Skye bioscience enters research agreements with university of eastern piedmont and spanish research council

Skye Bioscience inc (OTCQB:SKYE) said it has signed new research agreements with the University of Eastern Piedmont (UPO) in Italy and the Spanish Re...

June 7, 2022, 7:40 am

Outlook therapeutics opts to resubmit bla for wet amd drug after fda requests more info

Outlook Therapeutics (NASDAQ:OTLK) Inc said it has voluntarily withdrawn the biologics license application (BLA) for its ...

May 31, 2022, 10:26 am

Buy deep moated, fast growing, superbly managed harrow health ahead of new product launch

Harrow began commercial operations in 2014 with no products or customers, and today is the largest U.S. ophtha...

May 23, 2022, 3:12 pm


Search within

Pages Search Results: